BRAF V600E mutation
A single spelling change in the BRAF gene that jams a growth switch permanently on. It is found in half of melanomas and in some colon, thyroid, lung and brain tumours, and is treated with a BRAF pill plus a MEK pill.
V600E (valine to glutamate at position 600) is the commonest BRAF mutation; class II and III mutations behave differently and resist the same drugs. Dabrafenib-trametinib, encorafenib-binimetinib and vemurafenib-cobimetinib treat metastatic and adjuvant melanoma, with immunotherapy usually given first in metastatic disease (DREAMseq). Encorafenib-cetuximab treats BRAF-mutant colorectal cancer (BEACON), dabrafenib-trametinib has a tumour-agnostic approval including glioma and thyroid cancer, and the combination has moved into paediatric low-grade glioma. BRAF-mutant colorectal cancer is aggressive and often overlaps with MSI-high sporadic tumours.
Pages like this
not linked directly; found by shared links- PersonKeith T. Flaherty
Shares Vemurafenib, BRAF, Melanoma.
- TrialCOLUMBUS
Shares Vemurafenib, BRAF, Melanoma.
- PersonGrant McArthur
Shares Vemurafenib, BRAF, Melanoma.
- PairingBRAF inhibitor + MEK inhibitor
Shares BRAF, Melanoma, Colorectal cancer, Non-small-cell lung cancer.
- ProductCobimetinib
Shares Vemurafenib, BRAF, Melanoma.
- ProductLarotrectinib
Shares Tumour-agnostic (tissue-agnostic) approval, Thyroid cancer, Colorectal cancer, Non-small-cell lung cancer.
- IdeaTest intermittent dosing of targeted drugs to delay resistance, with honest priors
Shares BRAF, Melanoma, Non-small-cell lung cancer.
- TermTERT promoter mutation
Shares BRAF, Thyroid cancer, Melanoma.